COMPENDIUM ON FUNCTIONAL MEDICINE - Flipbook - Page 644
bacterial overgrowth: a randomized, double-blind,
placebo-controlled trial. Eur J Gastroenterol Hepatol.
2016;28(3):281-289.
[19] Pimentel M, Chow EJ, Lin HC. Normalization of lactulose
breath testing correlates with symptom improvement in irritable
bowel syndrome: a double-blind, randomized, placebo-controlled
study. Am J Gastroenterol. 2003;98(2):412-419.
[20] Shah A, Morrison M, Holtmann GJ. Gastroduodenal "dysbiosis":
a new clinical entity. Curr Treat Options Gastroenterol.
2018;16(4):591-604.
[21] Hollon J, Puppa EL, Greenwald B, Goldberg E, Guerrerio A,
Fasano A. Effect of gliadin on permeability of intestinal biopsy
explants from celiac disease patients and patients with non-celiac
gluten sensitivity. Nutrients. 2015;7(3):1565-1576.
[22] Fasano A. All disease begins in the (leaky) gut: role of
zonulin-mediated gut permeability in the pathogenesis of some
chronic inflammatory diseases. F1000Res. 2020;9:F1000 Faculty
Rev-69.
[23] Maes M, Leunis JC. Normalization of leaky gut in chronic
fatigue syndrome (CFS) is accompanied by a clinical
improvement: effects of age, duration of illness and the
translocation of LPS from gram-negative bacteria. Neuro
Endocrinol Lett. 2008;29(6):902-910.
[24] Cryan JF, O'Riordan KJ, Cowan CSM, et al. The
microbiota-gut-brain axis. Physiol Rev. 2019;99(4):1877-2013.
[25] Nam JH, Lee Y, Yang Y, et al. Dermatological disorders and
the gut-skin axis: a review. Biomedicines. 2022;10(2):364.
[26] Gatta L, Scarpignato C. Systematic review with meta-analysis:
rifaximin is effective and safe for the treatment of small intestine
bacterial overgrowth. Aliment Pharmacol Ther. 2017;45(5):604-616.
644
